MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities

Authors: Crinière, Emmanuelle; Kaloshi, Gentian; Laigle-Donadey, Florence; Lejeune, Julie; Auger, Nathalie; Benouaich-Amiel, Alexandra; Everhard, Sibille; Mokhtari, Karima; Polivka, Marc; Delattre, Jean-Yves; Hoang-Xuan, Khê; Thillet, Joëlle; Sanson, Marc¹

Source: Journal of Neuro-Oncology, Volume 83, Number 2, June 2007 , pp. 173-179(7)

Publisher: Springer

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

MGMT promoter methylation, which has been correlated with the response to alkylating agents, was investigated in a retrospective series of 219 glioblastomas (GBMs) treated with various modalities. MGMT methylation had no impact on survival for the whole group, but showed a significant advantage (17.1 months vs. 13.1) for patients treated with RT+ adjuvant chemotherapy (relative risk of death (RR) = 0.53; P = 0.041), particularly when patients received CT during the course of RT (MS = 19.9 months vs. 12.5 months; RR = 0.227, P = 0.001). This suggests that the prognostic impact of MGMT methylation is dependent on therapeutic modalities and schedules. MGMT methylation was not correlated with the main molecular alterations, such as 10q loss and p53 expression.

Keywords: Glioblastoma; Markers; Prognosis; MGMT; Chemotherapy

Document Type: Research article

DOI: 10.1007/s11060-006-9320-0

Affiliations: 1: Email: marc.sanson@psl.ap-hop-paris.fr

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$47.00 plus tax